Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Posted: March 25, 2022 at 2:21 am

RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a leading trade publication directed at optometrists.

Read the original post:
Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix

Related Posts